Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Patient's Perspective
- PMID: 33967058
- PMCID: PMC8543244
- DOI: 10.3233/JPD-212650
Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Patient's Perspective
Abstract
There is an urgent unmet need in the Parkinson's disease community-advanced therapies to modify the inevitable decline that occurs in those affected by this progressive neurodegenerative disease for which there is no cure. This will require collaboration from all stakeholders and central to those partnerships are patients themselves. But participation in clinical trials and clinical use of advanced therapies have their own risk profile above and beyond standard therapeutics as evidenced by past invasive procedures. Therefore, it is of utmost importance that clear, evidence-based information about these potential treatments be clearly communicated by those exploring their use to ensure safe and informed participation from the patient community. Likewise, patients must weigh the benefits of these treatments their limitations and risks in order to truly give informed consent to participate in bringing these treatments to the clinic. Here we explore these issues from the patient perspective.
Keywords: Parkinson’s disease; advanced treatments; clinical research; gene therapy; patient risk; patient-centered; recruitment; stem cell replacement.
Conflict of interest statement
The authors have no conflict of interest to report.
Similar articles
-
Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues.J Parkinsons Dis. 2021;11(s2):S147-S155. doi: 10.3233/JPD-212639. J Parkinsons Dis. 2021. PMID: 34092655 Free PMC article. Review.
-
Potential subjects' responses to an ethics questionnaire in a phase I study of deep brain stimulation in early Parkinson's disease.J Clin Ethics. 2012 Fall;23(3):207-16. J Clin Ethics. 2012. PMID: 23256400
-
Challenges to Informed Consent in First-In-Human Trials Involving Novel Treatments: A Case Study of Parkinson's Disease.J Parkinsons Dis. 2017;7(4):695-702. doi: 10.3233/JPD-171141. J Parkinsons Dis. 2017. PMID: 29103049 Free PMC article.
-
First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process.Parkinsonism Relat Disord. 2015 Aug;21(8):829-32. doi: 10.1016/j.parkreldis.2015.05.011. Epub 2015 May 19. Parkinsonism Relat Disord. 2015. PMID: 26004682
-
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective.J Parkinsons Dis. 2021;11(s2):S129-S134. doi: 10.3233/JPD-212563. J Parkinsons Dis. 2021. PMID: 33814466 Free PMC article. Review.
Cited by
-
Advanced therapies in Parkinson's disease: an individualized approach to their indication.J Neural Transm (Vienna). 2024 Nov;131(11):1285-1293. doi: 10.1007/s00702-024-02773-3. Epub 2024 Apr 13. J Neural Transm (Vienna). 2024. PMID: 38613674 Free PMC article. Review.
-
Towards improved access to device-aided therapies in advanced PD: the importance of cooperation of different disciplines.J Neural Transm (Vienna). 2023 Nov;130(11):1433-1441. doi: 10.1007/s00702-023-02664-z. Epub 2023 Jul 13. J Neural Transm (Vienna). 2023. PMID: 37439943 Review.
References
-
- Parkinson J (1817) An essay on the shaking palsy. Printed by Whittingham & Rowland, London.
-
- Wirdefeldt K, Odin P, Nyholm D (2016) Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: A systematic review. CNS Drugs 30, 381–404. - PubMed
-
- Moosa S, Martínez-Fernáandez R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS (2019) The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson’s disease. Mov Disord 34, 1243–1251. - PubMed
-
- Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): A multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17, 749–759. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous